Log In
Print
BCIQ
Print
Print this Print this
 

VY-AADC01

  Manage Alerts
Collapse Summary General Information
Company Voyager Therapeutics Inc.
DescriptionAdeno-associated virus (AAV) serotype 2 encoding the dopa decarboxylase (DDC; AADC) gene injected into the putamen
Molecular Target Dopa decarboxylase (DDC) (AADC)
Mechanism of ActionGene therapy
Therapeutic ModalityGene therapy: Viral vector: Adeno-associated virus (AAV)
Latest Stage of DevelopmentPhase I
Standard IndicationParkinson's disease (PD)
Indication DetailsTreat Parkinson's disease (PD)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$845.0M

$70.0M

$745.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today